Nyrada Inc. (ASX:NYR)

Australia · Delayed Price · Currency is AUD

0.4700

+0.0400 (9.30%)

Oct 16, 2026, 4:10 PM AEST

Market Cap	116.37M +29.8%
Revenue (ttm)	2.01M -16.1%
Net Income	-6.56M
EPS	-0.03
Shares Out	247.59M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	151,844
Open	0.4600
Previous Close	0.4300
Day's Range	0.4400 - 0.4700
52-Week Range	0.3150 - 1.4350
Beta	1.03
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 21, 2026

About Nyrada

Nyrada Inc., a clinical-stage biotechnology company, focuses on the discovery and development of small-molecule therapies for neuroprotection and cardioprotection indications in Australasia. Its lead candidate is Xolatryp, a small-molecule inhibitor targeting the transient receptor potential canonical ion channel subtypes 3, 6, and 7, which is in a Phase IIa clinical trial to treat myocardial ischemia, arrhythmia, stroke, and traumatic brain injury, as well as in a preclinical research stage for oncology indications. Nyrada Inc. was incorporate... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2017

Country United States

Stock Exchange Australian Securities Exchange

Ticker Symbol NYR

Full Company Profile

Financial Performance

In fiscal year 2026, Nyrada's revenue was 2.01 million, a decrease of -16.08% compared to the previous year's 2.40 million. Losses were -6.56 million, 35.3% more than in 2025.

Financial Statements